For America’s politicians, there are few simpler bogeymen to rail towards than pharma bosses. Solely a fifth of the nation has a constructive opinion of the business, in response to Gallup, a pollster—which means its executives rank under even property brokers within the public’s esteem. The attention-watering costs of many medicine in America have created the impression of a grasping business that exploits the sick.
